11
Participants
Start Date
August 20, 2012
Primary Completion Date
May 5, 2016
Study Completion Date
March 10, 2017
Lenalidomide
10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
Collaborators (1)
Celgene Corporation
INDUSTRY
National Cancer Institute (NCI)
NIH